ACE and pulmonary arterial hypertension: The activation of this pathway provides a shield against the adverse effects mediated by RAS or by the ACE/AngII/AT1R axis, such as lung inflammation, fibrosis, pulmonary arterial hypertension, and alveolar epithelial cell apoptosis [59].